🔬 AIIMS Delhi's Groundbreaking Discovery in Gut-Bone Research

Researchers at the All India Institute of Medical Sciences (AIIMS) Delhi have uncovered a fascinating connection between the gut microbiome and bone strength, potentially revolutionizing how we approach osteoporosis. Led by Dr. Rupesh K. Srivastava from the Department of Biotechnology, the study highlights deoxycholic acid (DCA)—a secondary bile acid produced by specific gut bacteria—as a key player in protecting bones from inflammatory damage. In mouse models simulating inflammatory bone loss, DCA supplementation not only restored bone mineral density but also balanced the gut ecosystem, offering hope for novel therapies.

This finding builds on the emerging 'gut-bone axis,' where trillions of microbes in our intestines influence skeletal health far beyond digestion. For India, where osteoporosis affects millions, particularly postmenopausal women, this research from a premier institution like AIIMS underscores the power of translational studies in addressing national health challenges.

Osteoporosis: A Silent Epidemic in India

Osteoporosis, characterized by reduced bone density and increased fracture risk, is a major public health concern. In India, prevalence among postmenopausal women ranges from 30% to 40%, with osteopenia—a precursor condition—affecting up to 44% in some regions. Studies indicate around 23% of women versus 11% of men are impacted, driven by factors like low calcium intake, vitamin D deficiency, and sedentary lifestyles prevalent in urban India. By 2050, Asia could see over 50% of global osteoporotic fractures, placing immense economic strain—estimated at billions in treatment and productivity losses—on India's healthcare system.

Postmenopausal estrogen decline accelerates bone resorption by osteoclasts (bone-breaking cells) while impairing osteoblast (bone-building) activity. Inflammation exacerbates this, but traditional treatments like bisphosphonates have side effects, prompting exploration of gut-derived solutions.

Decoding the Gut-Bone Axis

The gut houses over 100 trillion microbes that ferment food, produce metabolites like short-chain fatty acids and bile acids, and regulate immunity. The gut-bone axis describes how dysbiosis—imbalance in this microbiome—promotes systemic inflammation via leaky gut, leaking lipopolysaccharides (LPS) that trigger cytokines like TNF-α and IL-6, fueling osteoclast activity and bone loss.

Primary bile acids from the liver are modified by gut bacteria into secondary ones like DCA. DCA acts via receptors farnesoid X receptor (FXR) and Takeda G-protein receptor 5 (TGR5) on bone cells, suppressing osteoclastogenesis and boosting osteoblastogenesis. Reviews confirm bile acids modulate bone remodeling, with DCA restoring homeostasis.

The AIIMS Study Design and Methodology

Dr. Srivastava's Translational Immunology, Osteoimmunology & Immunoporosis Lab (TIOIL) at AIIMS used a lipopolysaccharide (LPS)-induced inflammatory bone loss model in mice, mimicking chronic conditions like postmenopausal osteoporosis. Mice received LPS injections (5 mg/kg on days 0 and 4) to induce dysbiosis and bone erosion over 11 days. Treatment groups included DCA supplementation, assessed via micro-CT for bone parameters, histomorphometry, serum cytokines, gut histology, and 16S rRNA sequencing for microbiome.

• Micro-CT: Analyzed trabecular (BV/TV, Tb.N, Tb.Sp) and cortical bone (Cs.Th, M.Ar) in femur/tibia.
• TRAP staining: Quantified osteoclasts.
• ALP/Alizarin Red: Osteoblast activity.
• ELISA: Cytokines (TNF-α, IL-6, etc.).
• Gut: H&E for villus length, tight junctions (claudin-1, occludin).

Key Findings: DCA Restores Bone and Gut Health

DCA dramatically reversed LPS damage. Micro-CT showed improved trabecular bone volume fraction (BV/TV), number (Tb.N), BMD in femur/tibia, and cortical thickness. TRAP staining revealed fewer osteoclasts; osteoblast assays confirmed enhanced mineralization. Serum levels: Reduced pro-inflammatory TNF-α, IL-6, IL-17, RANKL; elevated IL-10, TGF-β (anti-inflammatory, Treg-associated).

Gut histology: DCA mended leaky gut, boosting villus length and tight junctions. Microbiome: Restored Shannon diversity, Bacteroidota/Patescibacteria (up), Firmicutes (down). Dr. Srivastava notes, “DCA suppressed bone-resorbing cells and boosted bone-forming ones, improving formation.”

Molecular Mechanisms: FXR/TGR5 Signaling

DCA upregulates FXR/TGR5 in bone cells, inhibiting NFATc1/c-Fos (osteoclast markers) and promoting Runx2 (osteoblast). It curbs Th17 (IL-17 producers) while favoring Tregs (IL-10), balancing immunity. Prior TIOIL studies link probiotics to similar Treg modulation.

Building on Probiotics: TIOIL's Trailblazing Work

Dr. Srivastava's lab pioneered 'immunoporosis,' showing immune dysregulation drives bone loss. Recent papers: Bacillus coagulans (Gut Microbes 2025) improved BMD/microarchitecture via gut-immune-bone axis; Lactobacillus acidophilus modulated RORγt+ pTregs in postmenopausal models (J Cell Physiol 2025). These position Indian probiotics as osteoporosis adjuncts.

Treatment Implications for Indian Women

With 6 crore osteoporosis cases (80% women), India faces a crisis. DCA therapy—direct supplements or DCA-producing probiotics—could complement calcium/vit D. For postmenopausal women, where estrogen loss disrupts gut barrier, this is promising. Read the full study in Biomedicine & Pharmacotherapy. Human trials needed, but early screening via DEXA scans urged.

Boosting DCA Naturally: Diet and Lifestyle

• Fiber-rich foods (oats, beans) feed bile acid-modifying bacteria.
• Fermented dairy/probiotics (yogurt, idli) support secondary bile production.
• Omega-3s (fish, flax) reduce inflammation.
• Exercise maintains microbiome diversity.

Avoid antibiotics disrupting producers like Clostridium scindens.

Challenges, Future Outlook, and India's Research Leadership

Limitations: Mouse model; human DCA levels vary. Safety concerns (high DCA links to liver issues). AIIMS/TIOIL plans clinical trials. India's ICMR funding boosts microbiome research at IITs/IISERs. Explore AIIMS Biotechnology for collaborations.

This positions AIIMS as leader, inspiring higher ed focus on translational osteoimmunology.

Photo by Ibrahim Rifath on Unsplash